Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
NBIXthis companyNeurocrine Biosciences, Inc.	$169.16	29.49×	4.34×	4.93×	20.72×	115.2%	98.2%	21.6%	16.7%	14.7%	10.8%	5.3%	0.13×	-0.45×	0×	3.39×	0.0%	5	7.31	4	A
ACADAcadia Pharmaceuticals Inc.	$17.88	11.51×	3.69×	4.22×	29.19×	-248.1%	91.7%	9.8%	36.5%	31.9%	8.1%	2.3%	0.04×	-0.83×	0×	3.83×	0.0%	4	5.67	4	A-
AXSMAxsome Therapeutics, Inc.	$133.80	-49.63×	102.9×	14.23×	-53.57×	-426.6%	92.6%	-26.5%	-28.7%	-207.5%	-44.0%	-1.0%	2.73×	0.49×	-25.81×	1.55×	0.0%	3	4.12	1	D+
BHVNBiohaven Ltd.	$15.40	-1.65×	23.33×	0×	-1.75×	-103.9%	0.0%	0.0%	0.0%	-1418.8%	-218.4%	-50.2%	5.47×	-0.08×	0×	3.18×	0.0%	3	-15.54	2	C
NMRANeumora Therapeutics, Inc. Common Stock	$0.48	-1.23×	2.82×	0×	-0.47×	121.7%	0.0%	0.0%	0.0%	-228.1%	-151.8%	-70.6%	0×	0.78×	-74.92×	5.87×	0.0%	2	-18.14	2	C+
RAPPRapport Therapeutics, Inc. Common Stock	$26.18	-10.61×	2.44×	0×	-9.19×	-96.2%	0.0%	0.0%	0.0%	-23.0%	-25.2%	-7.5%	0.02×	0.33×	0×	26.17×	0.0%	3	24.43	2	C
Peer median	—	-1.65×	3.69×	0×	-1.75×	-103.9%	0.0%	0.0%	0.0%	-207.5%	-44.0%	-7.5%	0.04×	0.33×	0×	3.83×	0.0%	3	4.12	2	—